Innovation Pharmaceuticals Announces New Antiviral
Post# of 72440
(Total Views: 711)
Posted On: 06/28/2022 10:21:52 AM
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
Research was performed by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID)
WAKEFIELD, MA / June 28, 2022 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced new antiviral research on Brilacidin in vitro antiviral activity in bunyaviruses and alphaviruses has been accepted for a Poster Presentation at the 2022 Military Health System Research Symposium (MHSRS), taking place September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. Last year, Brilacidin antiviral findings were also accepted for presentation at the MHSRS, an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
As released last week, Brilacidin has been researched by NIH/NIAID-sponsored and other academic collaborators as a novel broad-spectrum antiviral drug candidate. A review article is being prepared on Brilacidin based on this research and on results from the Company’s Phase 2 clinical trial (NCT04784897) of intravenous Brilacidin in moderate-to-severe hospitalized cases of COVID-19.
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio
Research was performed by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID)
WAKEFIELD, MA / June 28, 2022 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced new antiviral research on Brilacidin in vitro antiviral activity in bunyaviruses and alphaviruses has been accepted for a Poster Presentation at the 2022 Military Health System Research Symposium (MHSRS), taking place September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. Last year, Brilacidin antiviral findings were also accepted for presentation at the MHSRS, an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
As released last week, Brilacidin has been researched by NIH/NIAID-sponsored and other academic collaborators as a novel broad-spectrum antiviral drug candidate. A review article is being prepared on Brilacidin based on this research and on results from the Company’s Phase 2 clinical trial (NCT04784897) of intravenous Brilacidin in moderate-to-severe hospitalized cases of COVID-19.
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio
(15)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼